Phibro Animal Health Corporation (PAHC)

From the record

Phibro Animal Health Corporation's filings since 2017 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

From the record

Phibro Animal Health Corporation's 7 filed years say what it did: revenue went from $800 million in fiscal 2020 to $1.5 billion in fiscal 2026, up 11.3% a year; it rose in 6 of 6 years; it never fell from a peak; net income was positive in 7 of 7 of those years (its annual reports).

From the record

Over the 3 fiscal years to 2026-06-30, Phibro Animal Health Corporation's diluted share count grew about 0.4% a year, and dividends and buybacks returned about 25% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 61 sales (61 under scheduled 10b5-1 plans) and 1 purchase of their own stock on the open market in the year to 2026-09-30, buying about $318 thousand (their Form 4 filings).

From the record

Return on equity: in the fiscal year ended 2026-06-30, Phibro Animal Health Corporation earned about 26 cents of profit for every dollar of shareholders' money, and gross profitability: its products earned about 34 cents per dollar of everything the company owns. Leverage: it owed about 74 cents per dollar of assets, and net share issuance: its share count grew 0.7% over the year (the filed statements).

From the record

Phibro Animal Health Corporation's standing among 315 graded names in its industry family: revenue of $1.5 billion in fiscal 2026 ranks in the top 10% by size; a net margin of 6.6% ranks in the top 20%; revenue growth of 15.8% a year over the last 3 filed years ranks in the top 41% (its annual reports).

From the record

Phibro Animal Health Corporation's leadership, from its insiders' filings and its current reports: the chief executive on the record is Bendheim, Daniel M (President and CEO, as filed), filing under that title since 2026-07-02, 4 months (bottom 5% of its family); the 10 officers and directors filing in the last fifteen months have been on the record a median of 9.2 years (top 12%); 6 officer or director changes were reported on Form 8-K since 2023-11-13, against the 10 people in charge now (bottom 33%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Phibro Animal Health Corporation's room to grow, from the newest filed statements (fiscal 2026): cash of $61 million against no long-term debt tagged leaves 4.1% of its assets as net cash, bottom 19% of its family; cash from operations less capital spending is 0.6% of revenue (top 28%); a gross margin of 33.8% (bottom 17%); research spending of 1.6% of revenue (bottom 3%) (its annual report).

From the record

Phibro Animal Health Corporation's growth drivers, from the filed years to fiscal 2026: revenue grew 15.8% a year over the last three filed years against 11.3% over all 7, speeding up (top 23% of its family); the newest year grew 17.1% (top 40%); research spending grew 0.2% a year (bottom 48%); capital spending grew 4.5% a year (top 34%) (its annual reports). Phibro Animal Health Corporation reported 3 lines of business in fiscal 2026: Animal Health at $1.2 billion (77%), Mineral Nutrition at $282 million (19%), Performance Products at $74 million (5%); 2 of 3 grew against the year before (its annual report).

From the record

Phibro Animal Health Corporation's newest year against its own record: revenue of $1.5 billion in fiscal 2026 came in 1.7% above the $1.5 billion its prior three years' pace pointed to (top 42% of its family); net income of $100 million against a prior three-year average of $28 million (top 5%); a net margin of 6.6% against 2.4% before (bottom 42%) (its annual reports).